We are live on
!
Find out more
DAM
DLD Asset Management Portfolio holdings
AUM
$1.51B
Turnover
51.11%
1-Year Est. Return
5.32%
This Fund
S&P 500
This Quarter
Est. Return
+15.08%
1 Year Est. Return
+5.32%
3 Year Est. Return
+10.27%
5 Year Est. Return
+32.59%
10 Year Est. Return
–
AUM
$1.85B
AUM Growth
-$122M
(-6.2%)
Cap. Flow
-$553M
Cap. Flow
% of AUM
-29.79%
Top 10 Holdings %
Top 10 Hldgs %
74.46%
Holding
121
New
44
Increased
20
Reduced
8
Closed
32
Avg Time Held Equity + Options
0.3
years
Top 10 Avg Time Held Equity + Options
0.3
years
Top 20 Avg Time Held Equity + Options
0.4
years
Avg Time Held Equity only
0.3
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TECD
Tech Data Corp
TECD
|
+$29.6M |
| 2 |
TIF
Tiffany & Co.
TIF
|
+$26.6M |
| 3 |
LPT
Liberty Property Trust
LPT
|
+$17.2M |
| 4 |
AGN
Allergan plc
AGN
|
+$16.2M |
| 5 |
MDCO
Medicines Co
MDCO
|
+$13.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$44.7M |
| 2 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$13.8M |
| 3 |
CBM
Cambrex Corporation
CBM
|
+$7.14M |
| 4 |
WBC
WABCO HOLDINGS INC.
WBC
|
+$7.02M |
| 5 |
GWR
Genesee & Wyoming Inc.
GWR
|
+$6.91M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 79.37% |
| 2 | Healthcare | 8.05% |
| 3 | Consumer Discretionary | 2.94% |
| 4 | Technology | 2.46% |
| 5 | Communication Services | 2.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
AXE
51
DELISTED
Anixter International Inc
AXE
| $1.84M | 0.1% |
+20,000
| New | +$1.62M |
2019 Q4
0 quarters
|
|
|
ZGNX
52
DELISTED
Zogenix, Inc.
ZGNX
| $1.56M | 0.08% |
+30,000
| New | +$1.37M |
2019 Q4
0 quarters
|
|
|
ZGNX
53
PUT
DELISTED
Zogenix, Inc.
ZGNX
| $1.56M | 0.08% |
+30,000
| New | +$1.37M |
2019 Q4
0 quarters
|
|
54
CALL
Axsome Therapeutics
AXSM
$8.25B
| $1.34M | 0.07% |
+13,000
| New | +$525K |
2019 Q4
0 quarters
|
|
55
Genworth Financial
GNW
$3.4B
| $1.32M | 0.07% |
+300,000
| New | +$1.26M |
2019 Q4
0 quarters
|
|
56
Gen Digital
GEN
$14.8B
| $1.28M | 0.07% |
50,000
-120,000
| -71% | -$2.93M |
2019 Q3
1 quarter
|
|
|
KDMN
57
DELISTED
Kadmon Holdings, Inc.
KDMN
| $1.27M | 0.07% |
+280,000
| New | +$1.02M |
2019 Q4
0 quarters
|
|
58
Telephone and Data Systems
TDS
$3.95B
| $1.22M | 0.07% |
+47,844
| New | +$1.17M |
2019 Q4
0 quarters
|
|
|
APTO
59
DELISTED
Aptose Biosciences, Inc.
APTO
| $1.14M | 0.06% |
+446
| New | +$581K |
2019 Q4
0 quarters
|
|
60
PUT
Cleveland-Cliffs
CLF
$7.15B
| $1.05M | 0.06% |
125,000
+110,000
| +733% | +$845K |
2019 Q3
1 quarter
|
|
|
IMMU
61
DELISTED
Immunomedics Inc
IMMU
| $1M | 0.05% |
+47,500
| New | +$838K |
2019 Q4
0 quarters
|
|
|
IMMU
62
PUT
DELISTED
Immunomedics Inc
IMMU
| $1M | 0.05% |
+47,500
| New | +$838K |
2019 Q4
0 quarters
|
|
63
DELISTED
BioXcel Therapeutics
BTAI
| $956K | 0.05% |
+4,088
| New | +$411K |
2019 Q4
0 quarters
|
|
64
DELISTED
KalVista Pharmaceuticals
KALV
| $891K | 0.05% |
+50,000
| New | +$653K |
2019 Q4
0 quarters
|
|
|
DRNA
65
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $881K | 0.05% |
+40,000
| New | +$805K |
2019 Q4
0 quarters
|
|
66
PUT
DELISTED
DURECT Corp
DRRX
| $649K | 0.04% |
+17,130
| New | +$353K |
2019 Q4
0 quarters
|
|
67
Anterix
ATEX
$1.62B
| $557K | 0.03% |
+12,888
| New | +$525K |
2019 Q4
0 quarters
|
|
|
OYST
68
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| $517K | 0.03% |
+21,147
| New | +$371K |
2019 Q4
0 quarters
|
|
|
PGNX
69
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $509K | 0.03% |
+100,000
| New | +$529K |
2019 Q4
0 quarters
|
|
|
CPE
70
CALL
DELISTED
Callon Petroleum Company
CPE
| $483K | 0.03% |
10,000
| – | – |
2019 Q3
1 quarter
|
|
71
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $461K | 0.02% |
+150,000
| New | +$390K |
2019 Q4
0 quarters
|
|
72
CALL
Wave Life Sciences
WVE
$633M
| $401K | 0.02% |
+50,000
| New | +$1.23M |
2019 Q4
0 quarters
|
|
73
Booking.com
BKNG
$124B
| $314K | 0.02% |
3,825
| – | – |
2019 Q1
3 quarters
|
|
74
CALL
DELISTED
Entera Bio Ltd. Warrant
ENTXW
| $64K | ﹤0.01% |
337,673
+13,001
| +4% | +$2.56K |
2019 Q1
3 quarters
|
|
75
CALL
Nabors Industries
NBR
$1.19B
| $29K | ﹤0.01% |
+200
| New | +$21.1K |
2019 Q4
0 quarters
|
|
Similar funds
FFM
AWA
SC
HCM
NB
WFA
RIM
AU
DLD Asset Management's Q4 2019 Portfolio in Review
As of Q4 2019, DLD Asset Management held 121 positions worth $1.85B, down 6.2% from $1.98B the previous quarter. Its ten largest holdings account for 74% of the portfolio.
DLD Asset Management withdrew a net $553M in Q4 2019, closing 32 positions and reducing 8 holdings. Its most notable exit was Celgene Corp, an estimated $44.7M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 79% of assets, down from 87% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, DLD Asset Management opened a new position in Tech Data Corp worth $33M.
- DLD Asset Management's largest Q4 2019 buy was Tech Data Corp: 230,000 shares worth $33M.
- DLD Asset Management added most to Allergan plc in Q4 2019, an estimated $16.2M increase.
- DLD Asset Management's biggest Q4 2019 reduction was WABCO HOLDINGS INC., cutting an estimated $7.02M.
- DLD Asset Management fully exited Celgene Corp in Q4 2019, selling an estimated $44.7M.
- DLD Asset Management's ten largest holdings make up 74% of its $1.85B portfolio in Q4 2019.
- DLD Asset Management opened 44 new positions and closed 32 in Q4 2019.
- DLD Asset Management's portfolio value fell 6.2% quarter-over-quarter to $1.85B.
Based on DLD Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.